Latest From Anthem Inc.
Pharmaceutical companies can struggle to understand the business opportunities presented by the federal segment, in part due to perceptions of low profit margins and overwhelming regulatory hurdles that are required to do business in this market. As companies begin to reframe the value of the federal market, it is important to establish context from a global revenue perspective.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
New commercial head Murdo Gordon described Aimovig as one of the best launches he's ever seen and said growth should continue – though moderate – based on prescriber experience and rapid transitions from free drug to reimbursed prescriptions.
Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.
- Therapeutic Areas
- Anthem Inc.
- WellPoint Inc.
- North America
- Parent & Subsidiaries
- Anthem Inc.
- Senior Management
Joseph R Swedish, Pres. & CEO
Wayne S DeVeydt, EVP & CFO
Craig Sammitt, MD, EVP & Chief Clin. Officer
- Contact Info
Phone: (317) 488-6000
120 Monument Cir.
Indianapolis, IN 46204
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.